
Medtronic (MDT) Stock Forecast & Price Target
Medtronic (MDT) Analyst Ratings
Bulls say
Medtronic is positioned for growth in the coming years, with its strong portfolio of therapeutic medical devices and expanding international presence. The recent acquisition of Scientia Vascular will likely drive faster growth in the neurovascular market, and the company is in the early stages of a strong product cycle. While there are potential risks such as market share loss and disappointing sales, Medtronic's strong financial performance and ongoing product innovation make it an attractive investment opportunity.
Bears say
Medtronic is actively pursuing growth through acquisitions, recently announcing a $550M cash acquisition of Scientia Vascular, which they expect to be accretive in FY27. However, the company's recent operating margin decline and inconsistent execution may hinder its ability to achieve high-single digit EPS growth and P/E multiple expansion.
This aggregate rating is based on analysts' research of Medtronic and is not a guaranteed prediction by Public.com or investment advice.
Medtronic (MDT) Analyst Forecast & Price Prediction
Start investing in Medtronic (MDT)
Order type
Buy in
Order amount
Est. shares
0 shares